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TRANSLATIONAL IMMUNOLOGY IN KIDNEY DISEASE, ISN NEXUS SYMPOSIUM 2016Aim: Primary: To study the incidence and mortality of CMV
disease (CMVD) in patients receivingno induction, before and after
universal prophylaxis.
Secondary: To study the clinical proﬁle of Early Versus Late
CMVD
Methods: Retrospective observational study. CMVD diagnosed
based on CMV DNA PCR/tissue histopathology in combination with
typical signs and symptoms.
Exclusion criteria: Age <18 years and patients who received
biologic agents as induction or in post-transplant period.
Study period: September 2013 – August 2015. All were ABO
compatible live renal transplant (RTx).
For analysis of Primary outcome, patients who received no in-
duction were divided into two groups: (I) All patients transplanted
after September 2014 received oral valganciclovir at a dose of
450mg O.D. for 100 days (UNIVERSAL PROPHYLAXIS GROUP)
(II) Patients transplanted before September 2014 received no
CMV chemoprophylaxis if they had not received induction with a
biologic agent.
All patients diagnosed with post RTx CMVD from September
2013 to August 2015 were included and divided into two groups for
analysis of Secondary outcome (A) Late CMV disease (>1yr post
RTx) (B) Early CMV disease (<1yr post RTx).
Results: 28 patients were included in the study (No induction
group). All had D+ / R+ CMV serology status pretransplant. Out of
12 patients in group (II), 5 developed CMVD (41.6%). 4 out of 5
patients with CMVD had expired (80%). Out of 16 patients in group
(I), no cases of CMVD were diagnosed and 1 patient out of 16 died
due to gram negative sepsis at the end of study period. A total of 8
patients were diagnosed with CMVD during the study period and
were included for secondary outcome analysis. 5 belonged to group
A and 3 to group B. The clinical proﬁle and outcomes are repre-
sented in Table 1.
Table 1.
Early CMVD Late CMVDS4No. of patients 5 3Immunosuppression TAC/MMF/Steroids CSA/AZA/SteroidsMean duration to
develop CMVD72 days post-transplant 8 yearsDisease
ManifestationsLeucopenia and opportunistic
infections (Disseminated
Strongyloidiasis and Nocardiosis)Tissue invasive disease
(CMV hepatitis, Gastritis
and retinitis)Mean CNI Levels Tac trough levels10.3ng/ml C2 levels 708mmol/LMean CMV copies 70,000 IU/ml 1054 IU/mlOutcomes 4/5 (80%) expired Responded well to
antivirals with good
patient outcomeConclusions: Incidence of CMVD was 41.6% with a high mortal-
ity(80%) in patients without universal CMV prophylaxis. Pro-
phylaxis with oral valganciclovir irrespective of induction/no
induction should be universalized to improve patient outcomes.
Early CMVD had a high incidence of life threatening opportunistic
infections resulting in poor patient outcomes versus patients with
late CMVD who had milder non-leucopenic tissue invasive CMVD
with better outcomes.
P08
BASOPHIL DYSFUNCTION IN CHRONIC
KIDNEY DISEASE PATIENTS
Aljadi, Z1, Nopp, A2, Winqvist, O2, Hylander, B3,
Jacobson, S4, Lundahl, J21Karolinska institute-Karolinska University Hospital, Department of medi-
cine, Stockholm, Sweden; 2Karolinska University Hospital- Karolinska
Institutet, Department of medicine, Stockholm, Sweden; 3Karolinska Uni-
versity Hospital- Karolinska Institutet, Department of Nephrology, Stock-
holm, Sweden; 4Karolinska Institutet- Danderyds Hospital, Division of
Nephrology- Department of Clinical Sciences, Stockholm, Sweden
Introduction: Chronic kidney disease (CKD) is one major medical
condition worldwide, which leads to signiﬁcant morbidity and
mortality. CKD patients have a signiﬁcant alteration in innate and
adaptive immune responses. Disturbance in innate immune re-
sponses in CKD patients has for example been represented by
dysfunction of neutrophil granulocytes as a consequence of chronic
activation leading to high levels of inﬂammatory cytokine. Given
the vital role of basophil cells in the pathogenesis of CKD; we aimed
to study the potential inﬂammatory response of basophils in
chronic kidney disease patients on hemodialysis.
Methods: The hemodialysis patients were recruited from the
Department of Nephrology at the Karolinska University Hospital in
Stockholm, Sweden. The estimated Glomerular Filtration Rate for
the patients was (eGFR) of <20 ml/min/1.73 m2 with a residual GFR
from 6-11. Patients were undergoing hemodialysis with polysulfone
high ﬂux dialyzers, three times per week for four to four and a half
hours per dialysis before the study (n¼10). Peripheral blood sam-
ples were drawn from patients before start of hemodialysis session.
The basophil surface expression of different activation markers
CD203c (basophil selection marker), CD63 (degranulation marker),
CD11b, active CD11b, CD62L (adhesive markers) and CD300a
(inhibitory marker of degranulation) were investigated, after
stimulation of different activation pathways in basophils with
Lipopolysaccharide (LPS), peptidoglycan (PGN), formyl-methyi-
noyl-leucyl-phenylalanine (fMLP), and anti- Fc RI antibody.
Results: The basophil expression of CD63 following activation by
fMLP was signiﬁcantly higher in the patient group compared to
healthy controls, but no differences were noted after activation by
anti-FcÉiRI-ab. CD300a expression was signiﬁcantly higher in pa-
tients following activation by fMLP and anti-FcÉiRI and the active
epitope CD11b expression was signiﬁcantly higher in patients after
LPS activation. In addition, we found that CD62L, in contrast with
that in neutrophils, was not shed from basophil surface after acti-
vation with LPS and fMLP but a signiﬁcant downregulation was
observed after activation with anti-FcÉiRI-ab in healthy controls.
Conclusions: In conclusion, these data show that basophil func-
tions related to adhesion and degranulation are altered in CKD
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Introduction: Persistent viral hepatitis C (HCV) is the main reason
for chronic liver diseases in patients on hemodialysis (HD). The ﬂow
of infectious process in this patients’ category has important dis-
tinctions. With chronic infections, the virus has a true mutagenic
effect.
The object of the present research was to study the level of
mutation variability in peripheral blood lymphocytes of patientsKidney International Reports (2016) 1, S1–S22
TRANSLATIONAL IMMUNOLOGY IN KIDNEY DISEASE, ISN NEXUS SYMPOSIUM 2016with end stage renal failure (ESRF ) on HD and burdened with
chronic viral hepatitis C (HCV).
Methods: Cytogenetic examination was performed in three patients
groups: 23 patients with ESRF on HD; 21 patient having HCV with
ESRF on HD; 29 patients with HCV without renal function disorder.
Lymphocytes were cultivated according to the conventional Hun-
gerford method for 52 hours with modiﬁcations. Selection of met-
aphasal plates for cytogenetic analysis, classiﬁcation and method for
calculation of chromosome aberrations were conventional. Multi-
aberrant cells were considered those having 3 aberrations and more.
Aneuploid cells were divided into hypoploid (under 42) and hy-
perploid ones (over 49).
Results: The frequency of chromosome aberrations was conﬁdently
different in all the three groups of patients examined and exceeded
the norm (by 3%). The highest indexes were in patients with HCV
(17,78  0,55%, P < 0,05) which was the cosequence of virus-
induced mutagenesis and were conﬁrmed by the data of other
authors. An intermidiate result (10,60  1,49%, P < 0,05) of chro-
mosome aberrations frequency in patients having HCV with ESRF
might suggest the impact of HD procedure on the chronic hepatitis
ﬂow in this patients’ category. In patients with ESRF this index was
conﬁdently lower than in other patients groups (4,69  0,51%).
In patients with ESRF on HD a number of aneuploid cells was
conﬁdently higher (20,0  0,97%, P < 0,05) and hence one may
suppose the presence of oncogenic component. In patients group with
HCV on HD and those without renal function disorder this index was
lower and made 14,12  1,69% and 16,32  0,53% accordingly. The
virus in case of a durable replicative phase is an inductor of a chain of
events leading to severe and mass demages of chromosome material.
This is conﬁrmed by the highest level of multiaberrant cells 7,71 
0,38% in patients with HCV. In patients with HCV on HD a number
of multiaberrant cells was conﬁdently lower and made 2,35  0,74%,
which didn’t differ from the indexes of patients with ESRF on HD
without hepatitis. In patients with HCV the largest chromosome
aberration spectrum was ﬁxed, that included acentric rings and
translocations, indicating its virus-induced damages.
A single hemodialysis procedure had no impact on the chro-
mosome aberrations level: the frequency of metaphases with aber-
rations remained on pre-dialysis level.
Conclusions:Hemodialysis procedure has an effect on the HCV ﬂow
and neutralizes the virus impact on genetic apparatus in case of
those pathologies combined. Our data allow one to explain and
conﬁrm the results of other researchers stating that the HCV ﬂow in
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Introduction: Chronic kidney disease (CKD) affects 8-16% people
worldwide, with an increasing incidence and prevalence of end-
stage kidney disease (ESKD). The effective management of CKD is
currently confounded by the inability to identify patients at high
risk of progression while still in early stages of CKD. Identifying the
mechanism responsible for progression of CKD is a critical step to
contain the worldwide CKD epidemic. A molecular disease deﬁni-
tion of CKD will allow us to develop strategies for patient risk
stratiﬁcation to prioritize limited health care resources, to identify
targeted molecular therapies for patients at high risk and to develop
biomarkers to deﬁne such patients for clinical trials. Our hypothesis
is that both clinical phenotypes (e.g. GFR, proteinuria) and renal
tissue alterations seen in CKD are associated with, and a conse-
quence of, the dynamic molecular mechanism reﬂected in the
transcriptional programs of the diseased renal tissue.
Methods: Our work started from the identiﬁcation and cross-vali-
dation of pathways and candidate intrarenal biomarkers for CKD
progression in 261 kidney biopsies. We then used a sequential
prioritization strategy to prioritize candidates for non- invasive
biomarkers to allow broad clinical applicability. Next, intra-renal
transcript levels of the top candidate biomarker were correlated
with the urinary levels of the encoded proteins. Urinary protein
levels were assessed for their correlation with CKD progression.
Finally, the biomarker was tested for its ability to increase pre-
dictive power of established clinical marker panels for CKD pro-
gression prediction in three cohorts. We used Cox proportional
hazards models to evaluate the predictive value of marker on CKD
outcome, and used likelihood ratio tests, C-statistics, and Akaike
information criterion (AIC) to assess the goodness of ﬁt and
improved prediction ability. Finally, we present our effort in
identiﬁcation the molecular disease mechanism, serving as targets,
to develop novel therapies to prevent CKD progression.
Results: Using Epidermal Growth Factor (EGF) as a proof of prin-
ciple, we could demonstrate that prediction of renal survival by
eGFR and albuminuria was signiﬁcantly improved by addition of
uEGF to the model in diverse CKD populations with a wide spec-
trum of causes and stages. uEGF may contribute to the improved
risk prediction as it can capture the degree of tubular differentia-
tion and regeneration potential, mechanisms essential to retain renal
function with the acute and chronic insults seen in CKD, but not be
well reﬂected by the conventional predictors (proteinuria or base-
line GFR).
Conclusions: uEGF shows promise as an independent risk predictor
of CKD progression. Inclusion of uEGF signiﬁcantly improved
prediction of composite end points by eGFR and proteinuria in
diverse populations worldwide with a wide range of CKD. An
immediate beneﬁt of our work can be an improved stratiﬁcation of
CKD patients for the selections of high-risk patients into clinical
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